

nal von minden GmbH \cdot Friedenstraße 32 \cdot 93053 Regensburg \cdot Deutschland

30.11.2021

Statement on the detectability of the Omicron virus variant of SARS-CoV-2 with the COVID-19 Ag tests of nal von minden GmbH

To whom it may concern.

Since the outbreak of the SARS-CoV-2 pandemic, several mutations of the SARS-CoV-2 coronavirus have occurred, resulting in a large number of variants. The Omicron variant (B.1.1.529) recently discovered in South Africa also has a large number of mutations. However, the majority of the mutations are in the spike protein, which the virus uses to recognize host cells.¹

However, our COVID-19 antigen rapid tests and self-tests detect the nucleocapsid protein, which encloses the RNA of the virus. By matching the mutations in the nucleocapsid protein of the Omicron variant, we expect our tests to remain successful in detecting the new virus variant. The *National Institute for Communicable Diseases* (NICD) also assumes that the performance of the rapid antigen tests will not be affected by the new mutations.²



² https://www.nicd.ac.za/frequently-asked-questions-for-the-b-1-1-529-mutated-sars-cov-2-lineage-in-south-africa/



Schnelltests

Labordiagnostika

Laborservice

Beratung & Service

nal von minden GmbH

Carl-Zeiss-Strasse 12 · 47445 Moers · Germany CEOs: Sandra von Minden · Roland Meißner · Thomas Zander Commercial reg. Kleve · HRB 5679

Phone: +49 941 290 10-0 · Fax: +49 941 290 10-50

¹ https://doi.org/10.1038/d41586-021-03552-w